Clinical TrialJun 24, 2026, 06:41 AM
Absci Reports Positive Interim Phase 1 Data for ABS-201
AI Summary
Absci Corporation announced positive interim Phase 1 data from its HEADLINE™ trial of ABS-201, a novel antibody targeting the Prolactin Receptor (PRLR). The study medication appeared well tolerated with a favorable safety profile across all single ascending dose (SAD) cohorts, reporting no serious adverse events. The estimated half-life of at least 65 days supports a potential dosing interval of two or three injections over a six-month period. The company has initiated the first multiple ascending dose (MAD) cohort in participants with androgenetic alopecia (AGA) and anticipates interim proof-of-concept data in the second half of 2026, with full data in early 2027.
Key Highlights
- ABS-201 Phase 1 interim data shows favorable safety and tolerability across all blinded single ascending dose (SAD) cohorts.
- No serious adverse events were reported, and all treatment-emergent adverse events were mild, except one moderate headache.
- Estimated half-life of ABS-201 is at least 65 days, supporting potential for 2-3 injections over a six-month period.
- The first multiple ascending dose (MAD) of ABS-201 has been initiated in participants with androgenetic alopecia (AGA).
- Interim proof-of-concept data for ABS-201 is anticipated in the second half of 2026.
- Full proof-of-concept data for ABS-201 is expected in early 2027.
- The Phase 1 trial (NCT07317544) included 32 healthy adult participants in four SAD cohorts (150 mg, 450 mg, 900 mg, 1800 mg IV).
Price Impact
More from ABSI